Your September e-Newsletter

ย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œย โ€Œ

View in browser

Hi John,


We hope you're keeping well. September often feels like a month of change. For many, sunny skies have made way for cloudy afternoons and whether it's the weather or the return to work and school, there's plenty of things shifting and on the move.


In lots of ways, the same can be said within the diabetes world. We've had a month of huge research announcements, including the start of a game-changing new era for type 1 diabetes treatment, plus draft guidance from NICE that could revolutionise treatment for type 2.


And whilst not everyone can spend their days doing incredible things inside a research lab, it doesn't mean that we can't make a difference outside one. We've got a run of autumn events on the horizon that we're excited to share with you, including our series of Wellness Walks and our 62 Miles in October challenge.


All that remains is to say thank you for your continued support. By simply taking the time to read this newsletter, you're staying connected, learning more about our work, and giving us the chance to share the impact your support is making.


And if we had one piece of advice - wrap up warm. It's getting colder next week!

Wellness Walks

Walk For Your Wellness

We've got two epic Wellness Walks coming up, with our flagship London Bridges event taking place on Sunday, 28 September and our brand new Manchester route kicking off on Sunday, 19 October. Both days are guaranteed to stick long in your memory as you walk with thousands of other people connected to our cause, take in the city sights, and fundraise for our vital work.

Sign up today

A huge research breakthrough

The first ever immunotherapy for type 1 diabetes has been licensed for use in the UK. The MHRA has concluded that teplizumabย is safe and effective at delaying the development of type 1 diabetes for people in the early stages of the condition. This is an incredible step forward and we'll continue fund world-class research that makes change like this possible.

Find out more

P.S. Did you know over 35% of our work is made possible thanks to gifts in Wills? A small gift, once youโ€™ve taken care of loved ones, could spark the research breakthroughs of tomorrow and rewrite the future for the next generation of people affected by diabetes. Find out more today.


Have a great start to the autumn,

Henry from Diabetes UK

Let us know how you felt about this email, John

๐Ÿ˜€

๐Ÿ˜

๐Ÿ™

Follow Diabetes UK

Get in touch

Contact us

Jobs

Useful information

About us

Helpline

Membership

Our strategy

View our Privacy and Cookies policies.


Diabetes UK is the operating name of the British Diabetic Association, a charity registered in England and Wales (no. 215199) and in Scotland (no. SC039136) A company limited by guarantee. Registered in England and Wales (no. 339181) VAT registration No. 232 3801 96. Registered office: Diabetes UK | 126 Back Church Lane | London E1 1FH | United Kingdom.


If you do not wish to receive further emails from us, please unsubscribe.